Anti-Hypertensive Drugs - Central Asia

Central Asia

The Anti-Hypertensive Drugs market in Central Asia is anticipated to witness a significant increase in revenue, projected to reach US$24.06m in 2024.
This growth is expected to continue with an annual growth rate (CAGR 2024-2029) of 1.17%, leading to a market volume of US$25.50m by 2029.
When compared globally, United States is predicted to generate the highest revenue in this market, with US$12,290.00m expected in 2024.
In Central Asia, the demand for anti-hypertensive drugs is rising due to the increasing prevalence of hypertension in the region.

Key regions: Japan, India, Italy, Brazil, South Korea

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Anti-Hypertensive Drugs in Central Asia has been on a steady rise in recent years.

Customer preferences: The primary customer base for Anti-Hypertensive Drugs in Central Asia are the elderly population, who are at a higher risk of developing hypertension. Additionally, the increasing prevalence of hypertension among the younger population, due to changing lifestyles and dietary habits, has also contributed to the growth of this market.

Trends in the market: One of the key trends in the Anti-Hypertensive Drugs market in Central Asia is the increasing use of combination therapies. Physicians are increasingly prescribing a combination of drugs to manage hypertension, as it has been found to be more effective than a single drug therapy. Another trend is the growing popularity of generic drugs, as they are more affordable and easily accessible to the masses.

Local special circumstances: Central Asia is a region with diverse cultural and economic backgrounds, and this has led to differences in the prevalence of hypertension and the demand for Anti-Hypertensive Drugs in different countries. For instance, Kazakhstan has a higher prevalence of hypertension compared to other Central Asian countries, and this has led to a higher demand for Anti-Hypertensive Drugs in the country.

Underlying macroeconomic factors: The rising healthcare expenditure and increasing government initiatives to improve healthcare infrastructure in Central Asia have been key drivers of the growth of the Anti-Hypertensive Drugs market in the region. Additionally, the increasing disposable income and changing lifestyles of the population have also contributed to the growth of this market. However, the lack of awareness about hypertension and its management among the population remains a major challenge for the growth of this market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.